SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor for topline data from OPUS-1 in Q4 2026, which could be a major catalyst. Until then, no new efficacy or safety data to assess; current market cap reflects future potential, not near-term fundamentals.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$55.94
T+0 close · Mar 23, 2026 · via day close
Latest settled
−9.42%
T+60 · $50.67
Vs SPY
−22.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $55.94entry
  2. T+1 · 8mo ago −2.27%α −1.91% · $54.67
  3. T+5 · 8mo ago −1.75%α +1.81% · $54.96
  4. T+20 · 7mo ago +8.24%α +0.82% · $60.55
  5. T+60 · 5mo ago −9.42%α −22.48% · $50.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2 Phase 3 trials for its investigational 31-valent pneumococcal vaccine VAX-31. Topline data from OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results anticipated in H1 2027. The trials are designed to support a future Biologics License Application (BLA) submission to the FDA, building on prior Breakthrough Therapy designation for VAX-31 in preventing invasive pneumococcal disease and pneumonia.

Key Facts

  • Enrollment completed in OPUS-1 (n≈4,000) and OPUS-2 (n≈1,300) Phase 3 trials for VAX-31.
  • Topline data from OPUS-1 expected in Q4 2026; OPUS-2 and OPUS-3 results expected in H1 2027.
  • OPUS-1 is a pivotal noninferiority trial comparing VAX-31 to Capvaxive® (PCV21) and Prevnar 20® (PCV20) in adults ≥50 years.
  • VAX-31 has FDA Breakthrough Therapy Designation for prevention of both IPD and pneumococcal pneumonia in adults.
  • No clinical results or financial figures reported, this is a program update on trial enrollment.

Financial Impact

No immediate financial impact; potential long-term value if VAX-31 demonstrates superiority and gains approval.

revenuevaluationR&D spend

Risk Factors

  • Clinical trial results may not meet endpoints despite favorable Phase 1/2 data.
  • Regulatory delays or failure to obtain BLA approval even with positive data.
  • High market expectations already priced in given $7.9B market cap despite being pre-revenue.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260381

US Market Status

Market Closed · Opens Thu (13h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026